ImaginAb Initiates Phase II Clinical Trial at Penn Medicine

LOS ANGELES, CA, December 9, 2019 – ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Penn Medicine in Philadelphia, PA. Penn Medicine is one of the world’s leading academic medical centers.

89Zr-Df-IAB22M2C is a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells. Using its ‘Minibody’ platform, ImaginAb’s technology targets and visualizes CD8+ T-cells to provide highly-specific, quantitative assessment of the immunological status of each cancer lesion within a patient, potentially enabling treatment to be tailored quickly and specifically to the needs of that patient.

Penn Medicine is one of ImaginAb’s active clinical sites conducting Phase II Baseline/On-Treatment clinical trial investigating the utility of 89Zr-Df-IAB22M2C to image CD8 T cells prior to (Baseline) and after (On-treatment) cancer patients receive immunotherapy-based treatment. Michael Farwell, MD, an Assistant Professor of Radiology in the Perelman School of Medicine at the University of Pennsylvania, is the study’s principal investigator.

Ian Wilson, CEO of ImaginAb, said: “ImaginAb’s goal is to provide target-specific imaging agents to evaluate immune responses in cancer patients in a safe and non-invasive manner and help realize the full potential of immunotherapy. We are delighted to add Penn Medicine to our CD8 Imaging Phase II trial and for enrollment in this ongoing clinical study.”

The trial will enroll advanced and metastatic cancer patients and will study the correlation of imaging signals observed using ImaginAb’s CD8 T cell ImmunoPET imaging agent, standard-of-care scans, and immunohistochemistry analysis of CD8 in biopsied tissues. The trial will also measure changes in CD8+ T-cell distribution before and after immuno-oncology therapies.

For further information please contact:

Ian Wilson
Email: [email protected]
Phone: +1 310 645 1211

Optimum Strategic Communications
Mary Clark, Supriya Mathur, Manel Mateus
Email: [email protected]
Phone: +44 20 3950 9144

About ImaginAb

ImaginAb Inc. is an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also developing a pipeline for other targets in oncology. ImaginAb’s products have the potential to improve patient care and lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms, including The Parker Institute for Cancer Immunotherapy, Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group.

For more information about ImaginAb’s pipeline and technology, visit